News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
US FDA to Review Easing Restrictions on Peptide Products; Hims & Hers (HIMS.US) Shares Rise 5%
The US Food and Drug Administration (FDA) will hold a two-day advisory committee meeting in July to discuss whether to allow licensed compounding pharmacies to resume manufacturing...
Reset
Send
The window will close in 5 seconds
US FDA to Review Easing Restrictions on Peptide Products; Hims & Hers (HIMS.US) Shares Rise 5%
Close
Recommend
1
Positive
1
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

The US Food and Drug Administration (FDA) will hold a two-day advisory committee meeting in July to discuss whether to allow licensed compounding pharmacies to resume manufacturing certain peptide products that were banned in 2023. Shares of Hims & Hers (HIMS.US)      rose 5%, extending the previous sessions 14% gain.

The review covers seven types of peptides. The related products are claimed to be used for wound healing, weight loss and improving insomnia, among other purposes, but human safety data remain limited.

Related NewsEIA Crude Oil Stocks Change for Apr/10 in the United States is -0.913M, lower than the previous value of 3.081M. The forecast was 0.2M.
(me/t)(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.